To empower the biomedical science community with cutting-edge proteomic technologies and advanced immune-profiling solutions that enable novel antigen discovery, accelerating disease understanding, diagnostics, and therapeutic development.

To create a new paradigm for immune profiling with unparalleled and unbiased antigen discovery technology, helping to expedite disease identification, accelerate the path to market for groundbreaking therapeutic interventions, and ultimately creating a low cost, routine diagnostic for patients everywhere.

Founded by Carnegie Mellon University Faculty, Impact Proteomics is a biotechnology company that has developed the first truly unbiased platform technology for immune-profiling and antigen discovery with a patient-specific approach. Our patent-pending solution enables researchers across academia and industry to identify new therapeutic and diagnostic targets in a way that existing immunoassays cannot, given their inherent bias towards previously known targets. 

Reflecting our academic roots, Impact Proteomics is a collaborative company that partners with customers and collaborators for a variety of use cases:

• Pharmaceutical and biopharmaceutical companies for target antigen/antibody identification & validation, in addition to patient stratification for clinical trials

• In Vitro Diagnostic (IVD) companies exploring new diagnostic protein markers or validating existing ones

• Academic and Non-profit disease research scientists seeking to identify novel disease-specific markers or complexes, or to validate existing hypotheses